“Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study”. 2023. SKIN The Journal of Cutaneous Medicine 7 (6): s254. https://doi.org/10.25251/skin.7.supp.254.